Skip to main content
FDA grants accelerated review for BeiGene's mantle cell lymphoma drug

The FDA has accepted BeiGene's marketing application for its BTK inhibitor zanubrutinib, granting the product Priority Review status, with Feb. 27, 2020, as the action date set by the agency. Zanubrutinib is indicated for mantle cell lymphoma patients who have undergone at least one previous line of therapy.

Full Story: